Skip to main content
OpenTrials

Clinical trial condition

Ovarian Seromucinous Carcinoma

Explore clinical trials studying Ovarian Seromucinous Carcinoma. Study availability and eligibility vary by location and protocol.

20 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Ovarian Seromucinous Carcinoma trial results

Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00951496

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine System Diseases, +55 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
View all 503 locations
View Trial Details
Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

NCT01097746

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +48 more
Locations
  • M D Anderson Cancer Center Houston, Texas, United States
  • MD Anderson Regional Care Center-Katy Houston, Texas, United States
  • MD Anderson Regional Care Center-Bay Area Nassau Bay, Texas, United States
  • MD Anderson Regional Care Center-Sugar Land Sugar Land, Texas, United States
View Trial Details
Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00888615

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +39 more
Locations
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • John Muir Medical Center-Concord Campus Concord, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California San Diego San Diego, California, United States
View all 163 locations
View Trial Details
Completed

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01504126

Conditions
Adnexal Diseases, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Diseases, +44 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Lyndon Baines Johnson General Hospital Houston, Texas, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • The Woman's Hospital of Texas Houston, Texas, United States
View Trial Details
Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01074411

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +41 more
Locations
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 14 locations
View Trial Details
Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT01459380

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +22 more
Locations
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
View all 13 locations
View Trial Details
Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01489371

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +22 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • University of New Mexico Cancer Center Albuquerque, New Mexico, United States
View Trial Details
Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

NCT01010126

Conditions
Adenocarcinoma, Adnexal Diseases, Adult Hepatocellular Carcinoma, +76 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles County-USC Medical Center Los Angeles, California, United States
View all 61 locations
View Trial Details

Related conditions